Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Interleukin-12 (IL-12)
100%
Th17 Response
100%
Ustekinumab
85%
Graft-versus-host Disease (GvHD)
42%
Transplantation
28%
Hematopoietic Cell Transplantation
28%
T Helper 17 (Th17)
28%
Alloresponse
28%
HLA-matched Donor
28%
Interleukin-23 (IL-23)
28%
T Helper 1
28%
Interleukin-17 (IL-17)
14%
Clinical Efficacy
14%
Placebo
14%
Tacrolimus
14%
Sirolimus
14%
Placebo-controlled Trial
14%
Lymphocytes
14%
Biological Impact
14%
T Regulatory
14%
Disease Relapse
14%
Interleukin-4 (IL-4)
14%
Subcutaneous Injection
14%
Peripheral Blood
14%
Non-relapse Mortality
14%
Overall Survival
14%
No Significant Difference
14%
Regulatory T (Treg) Cells
14%
National Institutes of Health
14%
Disease-free
14%
Donor Type
14%
IFN Production
14%
No Toxicity
14%
Graft-versus-host Disease Prophylaxis
14%
P40 Subunit
14%
Reactive Donors
14%
Relapse-free Survival
14%
Clinical Outcomes
14%
Impact Outcomes
14%
Medicine and Dentistry
Hematopoietic Cell
100%
Cell Transplantation
100%
Neutralization
100%
Ustekinumab
100%
Chronic Graft Versus Host Disease
33%
Interleukin 12
33%
Interleukin 23
33%
Placebo
33%
Regulatory T Cell
16%
Acute Graft Versus Host Disease
16%
Cytokine
16%
Subcutaneous Injection
16%
Overall Survival
16%
Recurrence Free Survival
16%
Rapamycin
16%
Graft Versus Host Reaction
16%
Tacrolimus
16%
Interleukin 17
16%
Interleukin 4
16%
Lymphocyte
16%
Non-Relapse Mortality
16%
Immunology and Microbiology
Neutralization
100%
Cell Transplantation
100%
Ustekinumab
100%
Hematopoietic Cell
100%
Chronic Graft Versus Host Disease
33%
Interleukin 23
33%
Interleukin 12
33%
Graft-Versus-Host Disease
16%
Regulatory T Cell
16%
Tacrolimus
16%
Sirolimus
16%
Acute Graft Versus Host Disease
16%
Overall Survival
16%
Recurrence Free Survival
16%
Cytokine
16%
Interleukin 4
16%
Lymphocyte
16%
Interleukin 17
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ustekinumab
100%
Placebo
33%
Chronic Graft Versus Host Disease
33%
Interleukin 12
33%
Interleukin 23
33%
Graft Versus Host Reaction
16%
Acute Graft Versus Host Disease
16%
Cytokine
16%
Overall Survival
16%
Interleukin 4
16%
Recurrence Free Survival
16%
Rapamycin
16%
Tacrolimus
16%
Subcutaneous Injection
16%
Interleukin 17
16%